Innovent Biologics has reported that two Phase III clinical trials, CREDIT-1 and CREDIT-4, analysing its antibody IBI306 for hypercholesterolemia met the primary endpoint. 

The company expects to submit a new drug application (NDA) for IBI306 in China to treat individuals with primary hypercholesterolemia and combined hyperlipidemia.

The double-blind, randomised, placebo-controlled CREDIT-1 trial analysed the safety and efficacy of IBI306 in non-familial hypercholesterolemia (non-FH) patients with high/very high cardiovascular risk in China. 

The percentage decline from baseline in low-density lipoprotein cholesterol (LDL-C) following treatment for 48 weeks was the primary efficacy goal of this trial.

The randomised, double-blind, placebo-controlled CREDIT-4 trial also evaluated the safety and efficacy of IBI306 in individuals with hypercholesterolemia including non-FH and heterozygous familial hypercholesterolemia (HeFH) in China.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

For this trial, the percentage decline in LDL-C from baseline following treatment for 12 weeks was the primary efficacy goal.

Results from both the trials showed that the LDL-C levels in the control arm were substantially lower as against the placebo arm. 

Furthermore, IBI306 was found to have a good safety profile in the trials, in line with those of other PCSK-9 inhibitors marketed currently.

An immunoglobulin G2 (IgG2) fully human monoclonal antibody, IBI306 attaches to proprotein convertase subtilisin/kexin type 9 (PCSK9). 

It thereby lowers the levels of LDL-C by hindering low-density lipoprotein receptor (LDLR) endocytosis mediated by PCSK-9.

This approach boosts LDL-C clearance causing a drop in the level of LDL-C.

Innovent executive director Dr Lei Qian said: “The results of these two clinical studies, CREDIT-1 and CREDIT-4, further confirmed the clinical significance of IBI306 in the treatment of patients with different types of hypercholesterolemia in China. 

“With the successive completion of various clinical studies, it is expected to propose a new drug application for IBI306 this year.”

In August last year, Innovent reported that IBI306 met the primary goal of the Phase III CREDIT-2 trial in HeFH patients in China.